0 (0%) | 03-28 15:18 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 232.23 | 1-year : | 271.24 |
Resists | First : | 198.83 | Second : | 232.23 |
Pivot price | 174.41 | |||
Supports | First : | 157.12 | Second : | 131.35 |
MAs | MA(5) : | 184.06 | MA(20) : | 174.92 |
MA(100) : | 133.16 | MA(250) : | 110.9 | |
MACD | MACD : | 9.9 | Signal : | 10 |
%K %D | K(14,3) : | 61.5 | D(3) : | 69.5 |
RSI | RSI(14): 72.3 | |||
52-week | High : | 198.83 | Low : | 74.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CEG ] has closed below upper band by 16.7%. Bollinger Bands are 45.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 190.2 - 191.48 | 191.48 - 192.54 |
Low: | 179.93 - 181.16 | 181.16 - 182.17 |
Close: | 183.08 - 185.09 | 185.09 - 186.74 |
Fri, 12 Jan 2024
Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL - Fierce Biotech
Tue, 19 Dec 2023
Celgene discovers new PADI4 inhibitors - BioWorld Online
Fri, 08 Sep 2023
Natco Pharma, Celgene Corp, others sued in US for generic cancer drug - Business Standard
Thu, 03 Aug 2023
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban - FiercePharma
Thu, 13 Jul 2023
Flagship recruits former BMS, Celgene R&D chief Rupert Vessey - STAT
Fri, 21 Apr 2023
Celgene, BMS, Teva Can't Pause Cancer Drugs Antitrust Suit - Law360
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 315 (M) |
Shares Float | 316 (M) |
Held by Insiders | 0.2 (%) |
Held by Institutions | 87.6 (%) |
Shares Short | 5,550 (K) |
Shares Short P.Month | 4,800 (K) |
EPS | 5.01 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 34.45 |
Profit Margin | 6.5 % |
Operating Margin | -2.5 % |
Return on Assets (ttm) | 2 % |
Return on Equity (ttm) | 13.9 % |
Qtrly Rev. Growth | -21 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 79.08 |
EBITDA (p.s.) | 13.13 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -5,300 (M) |
Levered Free Cash Flow | -1,610 (M) |
PE Ratio | 36.82 |
PEG Ratio | 0.9 |
Price to Book value | 5.35 |
Price to Sales | 2.33 |
Price to Cash Flow | -10.98 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |